Frontiers in Cell-Cycle-Targeting Therapies: Addressing the Heterogeneity of the Cancer Cell Cycle
Cancers · 21.01.2026 · 18 (2) · 329
DOI: 10.3390/cancers18020329 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancers, online erschienen am 21.01.2026. Verfasst von Ishaar P Ganesan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The cell division cycle machinery has been regarded as a promising therapeutic target for several decades. One of the most prominent milestones in the approach to targeting the cancer cell cycle was the development and approval of CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib. These small-molecule therapeutics have exhibited remarkable anti-cancer efficacy and have become primary choices for treating steroid receptor-positive breast cancer at multiple stages. This epoch-making success of cell-cycle-targeting drugs was followed by the development of small molecules to target other cell cycle-regulatory proteins, such as CDK2, CDK1, WEE1 kinase, Aurora kinases, and polo-like kinases, while therapeutic strategies to overcome resistance to CDK4/6 inhibitors have been pursued. In this article, we focus on heterogeneous vulnerabilities of cancers as consequences of various genetic and epigenetic alterations in the cell cycle-regulatory network, and we discuss how next-generation cell-cycle-targeting drugs currently in the developmental pipeline could exploit these heterogeneous vulnerabilities in the cancer cell cycle. We hope to provide a forward-looking perspective on directions for therapeutic cell-cycle targeting in the advent of personalized precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
ORCID-Profile: Hiroaki Kiyokawa
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Ganesan, I. P., & Kiyokawa, H. (2026). Frontiers in Cell-Cycle-Targeting Therapies: Addressing the Heterogeneity of the Cancer Cell Cycle. Cancers, 18(2), 329. https://doi.org/10.3390/cancers18020329
Vancouver
Ganesan IP, Kiyokawa H. Frontiers in Cell-Cycle-Targeting Therapies: Addressing the Heterogeneity of the Cancer Cell Cycle. Cancers. 2026;18(2):329. doi:10.3390/cancers18020329
BibTeX
@article{Ganesan2026,
author = {Ganesan, Ishaar P and Kiyokawa, Hiroaki},
title = {Frontiers in Cell-Cycle-Targeting Therapies: Addressing the Heterogeneity of the Cancer Cell Cycle},
journal = {Cancers},
year = {2026},
volume = {18},
number = {2},
pages = {329},
doi = {10.3390/cancers18020329}
}
EUVIMED